An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers  Amani Al-Khaifi, Mats Rudling, Bo Angelin  Gastroenterology  Volume 155, Issue 4, Pages 1012-1016 (October 2018) DOI: 10.1053/j.gastro.2018.06.038 Copyright © 2018 AGA Institute Terms and Conditions

Gastroenterology 2018 155, 1012-1016DOI: (10. 1053/j. gastro. 2018. 06 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Serum total and individual BAs, FGF19, and C4 in placebo group (A–C). Temporal responses (% of baseline) for serum total BAs, FGF19, and C4 (D, E, F) and serum lathosterol, total cholesterol, and triglycerides (G, H, I) for all subjects. Mean ± SEM. Arrows indicate meal (green) and drug (yellow) intake. Gastroenterology 2018 155, 1012-1016DOI: (10.1053/j.gastro.2018.06.038) Copyright © 2018 AGA Institute Terms and Conditions

Figure 2 Temporal responses (% of baseline) for serum FGF19 and C4 in all Px-102–treated groups. Mean ± SEM. Arrows indicate meal (green) and drug (yellow) intake. Significance of difference vs placebo group determined using 2-way analysis of variance with post hoc Dunnett's test. *P < .05; **P < .01; ***P < .001; ****P < .0001. Gastroenterology 2018 155, 1012-1016DOI: (10.1053/j.gastro.2018.06.038) Copyright © 2018 AGA Institute Terms and Conditions